Green Cross Market Cap ($278.32 Million)
Market Cap & Net Worth: Green Cross (005250)
Green Cross market cap. Green Cross (KO:005250) has a market capitalization of $278.32 Million (₩410.70 Billion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #14887 globally and #474 in its home market, demonstrating a -3.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Green Cross's stock price ₩9140.00 by its total outstanding shares 44934190 (44.93 Million). Also see Green Cross cash flow conversion for how efficiently the company converts equity into cash flow.
Green Cross Market Cap History (2015–2026)
Green Cross market cap history from 2015 to 2026. Data shows change from $1.16 Billion to $281.07 Million (-11.22% CAGR). Check today's stock price for Green Cross for real-time trading data and today's change.
Green Cross Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Green Cross's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Green Cross annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Green Cross's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Green Cross's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.16 Billion | $1.13 Trillion | $65.42 Billion | 0.00x | 0.02x |
| 2016 | $665.44 Million | $1.35 Trillion | $47.18 Billion | 0.00x | 0.01x |
| 2017 | $1.11 Billion | $1.46 Trillion | $43.36 Billion | 0.00x | 0.03x |
| 2018 | $714.54 Million | $1.55 Trillion | $18.47 Billion | 0.00x | 0.04x |
| 2019 | $642.80 Million | $1.52 Trillion | $2.96 Billion | 0.00x | 0.22x |
| 2020 | $1.22 Billion | $1.72 Trillion | $170.96 Billion | 0.00x | 0.01x |
| 2021 | $808.12 Million | $1.84 Trillion | $55.27 Billion | 0.00x | 0.01x |
| 2022 | $517.67 Million | $2.08 Trillion | $32.82 Billion | 0.00x | 0.02x |
| 2023 | $497.88 Million | $2.06 Trillion | -$54.14 Billion | 0.00x | N/A |
| 2024 | $527.42 Million | $2.20 Trillion | $24.03 Billion | 0.00x | 0.02x |
Competitor Companies of 005250 by Market Capitalization
Companies near Green Cross in the global market cap rankings as of November 3, 2026. Also see Green Cross total assets for a full breakdown of the balance sheet.
Key companies related to Green Cross by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Green Cross (2015–2026)
Market capitalization of Green Cross from 2015 to today. Between 2015 and today, Green Cross's market cap moved from $1.16 Billion to $ 281.07 Million, with a yearly change of -11.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩281.07 Million | -42.02% |
| 2025 | ₩484.78 Million | -8.08% |
| 2024 | ₩527.42 Million | +5.93% |
| 2023 | ₩497.88 Million | -3.82% |
| 2022 | ₩517.67 Million | -35.94% |
| 2021 | ₩808.12 Million | -33.61% |
| 2020 | ₩1.22 Billion | +89.37% |
| 2019 | ₩642.80 Million | -10.04% |
| 2018 | ₩714.54 Million | -35.40% |
| 2017 | ₩1.11 Billion | +66.22% |
| 2016 | ₩665.44 Million | -42.53% |
| 2015 | ₩1.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Green Cross was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $278.32 Million USD |
| MoneyControl | $278.32 Million USD |
| MarketWatch | $278.32 Million USD |
| marketcap.company | $278.32 Million USD |
| Reuters | $278.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Green Cross
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pert… Read more